adamantane has been researched along with Koch's Disease in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 3 (21.43) | 2.80 |
| Authors | Studies |
|---|---|
| Chaturvedi, S; Das, G; Dwivedi, VP; Jain, P; Kumar, S; Kumari, A; Pahuja, I; Prasad, DVR; Singh, B; Singh, M | 1 |
| Jackson, M; Kopál, M; Korduláková, J; Madacki, J | 1 |
| Karkara, BB; Kumar, A; Panda, G | 1 |
| Anastasiou, K; Foscolos, AS; Georgiadis, MO; Karalis, V; Kellici, T; Ladia, P; Lentzos, D; Mavromoustakos, T; Papanastasiou, I; Siamidi, A; Spaneas, D; Vlachou, M | 1 |
| Clemens, DL; Dillon, BJ; Ho, CM; Horwitz, MA; Lee, BY; Masleša-Galić, S; Nava, S; Silva, A | 1 |
| Cheng, X; Guddat, LW; Jiang, B; Jiang, H; Li, J; Liu, Z; Rao, Z; Wu, L; Yang, H; Yang, X; Yang, Y; Zhang, B; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Jeong, BH; Koh, WJ; Kwon, YS | 1 |
| Bagchi, S; Sharma, A; Wadhwa, P | 1 |
| Ginsberg, AM | 1 |
| Andries, K; Barry, CE; Nacy, CA; Protopopova, M; Sacksteder, KA | 1 |
| Einck, L; Nacy, CA; Nikonenko, BV; Protopopova, M; Samala, R | 1 |
| Spigelman, MK | 1 |
6 review(s) available for adamantane and Koch's Disease
| Article | Year |
|---|---|
Novel candidates in the clinical development pipeline for TB drug development and their synthetic approaches.
Topics: Adamantane; Animals; Antitubercular Agents; DNA Gyrase; Drug Development; Enzyme Inhibitors; Humans; Isonicotinic Acids; Mycobacterium tuberculosis; Oxazolidinones; Piperidines; Pyrroles; Structure-Activity Relationship; Tuberculosis; Tuberculosis, Multidrug-Resistant; Uridine | 2021 |
Tuberculosis: clinical trials and new drug regimens.
Topics: Acetamides; Adamantane; Antitubercular Agents; Clinical Trials as Topic; Diarylquinolines; Drug Administration Schedule; Drug Design; Ethylenediamines; Female; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Male; Moxifloxacin; Nitroimidazoles; Oxazoles; Oxazolidinones; Spiro Compounds; Thiazines; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2014 |
Drugs in development for tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Discovery; Ethylenediamines; Humans; Quinolines; Tuberculosis | 2010 |
Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action.
Topics: Adamantane; Animals; Antitubercular Agents; Drug Discovery; Drug Interactions; Drug Resistance, Multiple, Bacterial; Ethylenediamines; Humans; Mice; Mycobacterium tuberculosis; Tuberculosis | 2012 |
New tuberculosis therapeutics: a growing pipeline.
Topics: Adamantane; Animals; Antitubercular Agents; Clinical Trials as Topic; Diamines; Diarylquinolines; Ethylenediamines; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Tuberculosis | 2007 |
SQ109.
Topics: Adamantane; Animals; Antitubercular Agents; Ethylenediamines; Humans; Treatment Outcome; Tuberculosis | 2008 |
8 other study(ies) available for adamantane and Koch's Disease
| Article | Year |
|---|---|
The 1, 2-ethylenediamine SQ109 protects against tuberculosis by promoting M1 macrophage polarization through the p38 MAPK pathway.
Topics: Adamantane; Animals; Antitubercular Agents; Ethylenediamines; Macrophages; Mice; Mycobacterium tuberculosis; p38 Mitogen-Activated Protein Kinases; Tuberculosis | 2022 |
Mycobacterial Epoxide Hydrolase EphD Is Inhibited by Urea and Thiourea Derivatives.
Topics: Adamantane; Epoxide Hydrolases; Gene Expression Regulation, Bacterial; Humans; Mycobacterium tuberculosis; Phenylurea Compounds; Thioacetazone; Thiourea; Tuberculosis; Urea | 2021 |
In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II).
Topics: Adamantane; Administration, Oral; Antitubercular Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; Drug Compounding; Drug Liberation; Ethers; Ethylenediamines; Excipients; Hydrogen-Ion Concentration; Solubility; Tablets; Tuberculosis | 2017 |
Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.
Topics: Adamantane; Animals; Antitubercular Agents; Clofazimine; Diarylquinolines; Disease Models, Animal; Drug Combinations; Ethylenediamines; Humans; Lung; Mice; Mycobacterium tuberculosis; Pyrazinamide; Tuberculosis | 2018 |
Crystal Structures of Membrane Transporter MmpL3, an Anti-TB Drug Target.
Topics: Adamantane; Antitubercular Agents; Bacterial Proteins; Biological Transport; Drug Delivery Systems; Drug Design; Ethylenediamines; Humans; Membrane Proteins; Membrane Transport Proteins; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Phenylurea Compounds; Rimonabant; Tuberculosis | 2019 |
3D-QSAR Selectivity Analysis of 1-Adamantyl-3-Heteroaryl Urea Analogs as Potent Inhibitors of Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Bacterial Proteins; Computer-Aided Design; Drug Discovery; Epoxide Hydrolases; Humans; Membrane Transport Proteins; Molecular Docking Simulation; Mycobacterium tuberculosis; Quantitative Structure-Activity Relationship; Tuberculosis; Urea | 2015 |
Saxagliptin and tuberculosis.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglycemic Agents; Risk Factors; Tuberculosis | 2013 |
Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs.
Topics: Adamantane; Animal Experimentation; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Therapy, Combination; Ethylenediamines; Lung; Mice; Mycobacterium tuberculosis; Treatment Outcome; Tuberculosis | 2007 |